Anti-Human CD19 (Tafasitamab) [Clone MOR-208] - 50 mg

Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

CD19 is a B cell surface glycoprotein that enhances B cell receptor signaling and tumor cell proliferation 1. CD19 is an attractive immunotherapy target for cancers of lymphoid origin due to its early and persistent expression throughout B cell maturation 2. Tafasitamab is a humanized anti-CD19 monoclonal antibody developed by MorphoSys AG under a license from Xencor for the treatment of B cell malignancies 1. The chimeric antibody was engineered by combining the variable region genes of mouse anti-CD19 antibody (clone 4G7) with human light chain κ and heavy chain constant regions 1, 2. Light and heavy chain constructs were co-transfected into 293E cells and antibodies were purified using protein A chromatography 2. Additionally, the Fv of 4G7 was humanized, affinity-matured using library design automation, and substitutions S239D/I332E were introduced to increase Fcγ receptor affinity to human 2, mouse 2, and cynomolgus monkey 3 FcγRs, with FcγRIIIa affinity being particularly enhanced 2. Tafasitamab mediates B cell lysis via apoptosis and immune effector mechanisms including antibody-dependent cellular cytotoxicity (ADCC) 2, 4 and antibody-dependent cellular phagocytosis 2. Tafasitamab also increases antiproliferative activity and inhibits lymphoma growth in mouse xenograft models. ADCC is mediated by natural killer cells 5 through a granzyme B-dependent mechanism that is further enhanced by lenalidomide 6, 7. Tafasitamab is also known as XmAb5574 1.

≥ 5.0 mg/ml

CD19 is a surface antigen present on all B cells (healthy and malignant) except hematopoietic stem cells and plasma cells; it is highly conserved in B-cell malignancies.